Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05878119 · ClinicalTrials.gov registry record · Phase 2
Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program
A Phase 2 study of Healthy, sponsored by Metro International Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 1
- Study location
NCT05878119: Completed Phase 2 study of Healthy, sponsored by Metro International Biotech.
NCT05878119 is a Phase 2 study of Healthy that has completed, run by Metro International Biotech. The registered enrollment target is 124 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05878119, a Phase 2 study of Healthy, has completed, sponsored by Metro International Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 1
- Study location
Study Summary
A single-center, randomized, placebo-controlled study in community dwelling, healthy, regularly exercising, highly physically fit men and women, 19 to 40 years. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily for 10 weeks.
Primary Outcome
To determine the effects of MIB-626 (microcrystalline β-Nicotinamide Mononucleotide), administered at a dose of 1000-mg twice daily for 10 weeks, with and without a standardized multidimensional program of progressive high intensity exercise training on aerobic capacity, assessed as VO2 max measured during a standardized increasing work rate treadmill protocol, in community living, healthy, regularly exercising, highly physically fit, men and women, 19 to 40 years, inclusive.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Investigational Product - MIB 626
- OTHER Standardized, progressive, high intensity, multidimensional exercise
- OTHER Usual Physical Activity
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2025-08-04 |
| Phase | Phase 2 |
What the finished NCT05878119 record still lists
NCT05878119 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05878119 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05878119 about?
NCT05878119 is a clinical study titled "Effects of MIB-626 With and Without A High-Intensity Multi-Dimensional Exercise Training Program". A single-center, randomized, placebo-controlled study in community dwelling, healthy, regularly exercising, highly physically fit men and women, 19 to 40 years. Eligible participants will be randomized to receive either 1000 mg NMN or placebo twice daily for 10 weeks.
What is the current status of trial NCT05878119?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2023-10-25. Estimated completion is 2025-08-04.
What conditions does trial NCT05878119 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05878119?
The interventions under investigation include: Placebo (DRUG), Investigational Product - MIB 626 (DRUG), Standardized, progressive, high intensity, multidimensional exercise (OTHER), Usual Physical Activity (OTHER).
Who is sponsoring clinical trial NCT05878119?
This trial is sponsored by Metro International Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05878119 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05878119's enrollment target sits among peer trials
124 178th of 1090 higher than 913 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Effects of an Antioxidant Supplement on Blood Vessel Health
RECRUITING · Phase 2
-
Atenolol for the Prevention of Osteoporosis (APO)
ACTIVE NOT RECRUITING · Phase 2
-
Effectiveness of Aquamin® in Mitigating Halitosis
ACTIVE NOT RECRUITING · Phase 2
-
Effects of Nitrite on Blood Vessel Dilation in Normal Volunteers
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI